Amanta Healthcare IPO

About Amanta Healthcare IPO

The offer consists of a fresh issue component. The fresh issue will include up to 1,00,00,000 equity shares aggregating up to ₹126.00 crore. The total number of shares is 1,00,00,000 and the aggregate amount is ₹126.00 crore.

The IPO is opening on 01 September 2025 and closing on 03 September 2025. The listing date is 09 September 2025. The allotment of shares will take place on 04 September 2025. The credit of shares to the demat account will take place on 08 September 2025. The initiation of refunds will take place on 08 September 2025.

Incorporated in the year 199 4, Amanta Healthcare Limited has a well-diversified product portfolio of sterile liquid products across six therapeutic segments, viz. Fluid Therapy, Formulations, Diluents, Ophthalmic, Respiratory Care and Irrigation Solutions. In terms of container offerings, they offer a wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types, and container fill-volumes ranging from 2ml to 1000ml. Their formulation and development operations help them to develop new formulations as well as modify/improve formulations for their own brand and for their customers in their product partnering business. They have a dedicated Formulation and Development (“F&D”) and quality control laboratory located at their manufacturing facility in Hariyala, District Kheda, Gujarat, India.

Objective of Amanta Healthcare IPO

• Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up the new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.

• Funding capital expenditure requirements towards purchase of equipment, plant and machinery for setting up a new manufacturing line for Small Volume Parenteral (SVP) at Hariyala, Kheda, Gujarat.

• General corporate purposes.

Industry Outlook

The IV fluid market, consisting of key products like normal saline, dextrose, lactate ringer and electrolytes, has seen traction in recent years owing to growth of the overall healthcare system in India. The Indian IV fluids market is estimated to be valued at ₹4,500-4,700 crore as of fiscal 2024, compared to ₹2,900 crore in fiscal 2019. This growth was supported by multiple factors including rising population, increasing prevalence of chronic diseases, and growing demand for IV fluids in medical treatments due to their fast-acting nature.

Going ahead, with growth of the overall healthcare delivery market in India and the factors outlined above, the industry is estimated to register a CAGR of ~9-11% between fiscals 2024–2029 and reach ₹7,000-8,000 crore by fiscal 2029 owing to sustained demand from end-use segments like hospitals and clinics. The healthcare budget has seen increases year-on-year. Between FY11 and FY25, the budget for the MoHFW clocked a CAGR of ~10%. In recent years, the utilisation rate has been 100% or above, as has been the case since FY16. This, too, is a strong growth driver for the industry and particularly the PPP initiative from the government so as to achieve the government’s goal of providing healthcare services to all (Source: CRISIL Report).

Company Information

Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic containers with Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technology. They manufacture large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) in six therapeutic segments. In addition to that, they also manufacture medical devices. They manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in the therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in the medical device segment. They offer a wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volumes ranging from 2ml to 1000ml.

They market their products through three strategic business units, namely (a) national sales, (b) international sales and (c) product partnering with various foreign and Indian pharmaceutical companies. They manufacture a diverse generics product portfolio of over 45 products and market them under their own brands in the Indian market through a network of over 320 distributors and stockists. They sell their products in various countries including Africa, Latin America, the UK and the Rest of the World. Their Company’s products are currently registered in 19 countries and have a compliance track record with a range of regulatory regimes across these markets. During the fiscal 2025, they exported branded products to 21 countries. In product partnering, the company undertakes manufacturing for various pharmaceutical companies.

Strengths of Amanta Healthcare IPO

• Well-established manufacturer of pharmaceutical formulations with a diverse product portfolio and diverse markets.
• Large manufacturing capabilities.
• Wide domestic and international marketing network.
• Experienced management team supported by a large, diverse and skilled workforce.

Risks of Amanta Healthcare IPO

• Any delay in production at, or shutdown of, their manufacturing facility due to various factors such as a shortage of electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and an outbreak of infectious diseases.

• Any manufacturing or quality control concerns or their inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by their clients and distributors.

• Their operations are labour-intensive, and they may be subject to strikes, work stoppages or increased wage demands by their employees, an increase in minimum wages across various states and they may also be unable to engage new employees at commercially attractive terms.

• Loss of suppliers of LDPE (Low-Density Polyethylene) and PP granules (Polypropylene), or any fluctuation in the prices of these raw materials.

• Significant dependence on imported plastic granules, the primary packing material, exposes the company to risks such as import duties and regulatory or market concerns regarding source countries.

• Inability to respond adequately to the increased competition or pricing pressure they expect to face.

• The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose them to litigation or other liabilities.

• Inability to accurately forecast demand for their products and manage their inventory.

• Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters.

• Failure, inadequacy or breach of their information technology systems or their business processes regarding confidential information and other data, unauthorised access to their confidential information or violations of data protection laws.

Anchor Investor Bidding Date: 29 August 2025*

*The Company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date.

Registrar: MUFG Intime India Private Limited Book Running Lead Managers: Beeline Capital Advisors Private Limited

Business Model

The company earns its revenue through the following sources:

• Developing, manufacturing, and marketing a diverse range of sterile liquid products. Their product portfolio is categorised into six therapeutic segments: fluid therapy (IV fluids), formulations, diluents and injectables, ophthalmic solutions, respiratory care, and irrigation solutions.
• Manufacture of products like irrigation, first-aid solution, eye lubricants etc. in medical device segment.
• They also offer a wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2 ml to 1000 ml.

Company Growth Trajectory

Amanta Healthcare Limited shows fluctuating revenue performance, with total income decreasing by 1.96% from ₹281.61 crore in fiscal 2024 to ₹276.09 crore in fiscal 2025.

Their revenue from operations decreased by 2.01% from ₹280.34 crore in fiscal 2024 to ₹274.71 crore in fiscal 2025, primarily due to a decrease in the sale of products.

Their other income increased by 9.37% from ₹1.27 crore in fiscal 2024 to ₹1.39 crore in fiscal 2025, primarily as a result of an increase in the net fair value gain on financial assets measured at fair value.

Their restated profit for the year in fiscal 2025 was ₹10.50 crore compared to a restated profit for the year of ₹3.63 crore in fiscal 2024, which is an increase of 189.02%.

Company Market Position

Amanta Healthcare Limited sells its products in various countries including Africa, Latin America, the UK and the Rest of the World. The company’s products are currently registered in 19 countries and have a compliance track record with a range of regulatory regimes across these markets. During fiscal 2025, they exported branded products to 21 countries.

As on 31st March, 2025, the company’s Total Income, Profit After Tax, and EBITDA stood at ₹276.093 crores, ₹10.501 crores, and ₹61.054 crores, respectively.

How To Check Allotment Status of Amanta Healthcare Limited IPO?

You can check the allotment status of shares either on the website of the Bombay Stock Exchange (BSE) or on the website of the registrar MUFG Intime India Private Limited. To check the status on the BSE website:

• Visit the BSE website
• Click on “Investor Services” and choose “Application Status Check”
• Choose the issue type — Equity or Debt (Equity in this case)
• Select the Issue Name from the drop-down. The issue name is the company’s name, which is Amanta Healthcare Limited
• Enter your application number or PAN number
• Check the box which says “I’m not a Robot” and click on “Search” to know the allotment status

Follow these steps to know the allotment status on the registrar’s website:

• Visit the MUFG Intime India Private Limited website
• Choose “Public Issues” from the “Investor Services” drop-down
• Select Amanta Healthcare Limited from the drop-down
• Enter your PAN number or Application number
• Click on “Submit” to know the allotment status